Upload
vivien
View
19
Download
0
Tags:
Embed Size (px)
DESCRIPTION
That Patient Who Will Not Quit – A New Treatment Option. April 18, 2007 Michael C. Fiore, MD, MPH Professor of Medicine Director, Center for Tobacco Research and Intervention University of Wisconsin School of Medicine and Public Health. Disclosure Statement. - PowerPoint PPT Presentation
Citation preview
That Patient Who Will Not Quit – A New Treatment Option
April 18, 2007
Michael C. Fiore, MD, MPHProfessor of MedicineDirector, Center for Tobacco Research and InterventionUniversity of Wisconsin School of Medicine and Public Health
Over the last year, I have served as an investigator in research studies at the University of Wisconsin that were funded by Pfizer. In 1998, I was appointed to a named Chair made possible by an unrestricted gift to UW from GlaxoWellcome to the University of Wisconsin.
Disclosure Statement
Case Study
Mr. and Mrs. S
• Both late 60s
• Both NIDDM
• Both Hyperlipidemia
• Both BMIs over 35
• Both smoke more than a ppd and have tried to quit many times
A New Quit Attempt
Varenicline Quit Line
Varenicline
Approved by FDA in May, 2006 Marketed as Chantix A non-nicotine medication A selective 42 Nicotinic
Acetylcholine Receptor Partial Agonist
Varenicline: A Highly Selective 42 Receptor Partial Agonist
Chantix
Chantix is an 42 nicotinic receptor partial agonist, a compound with dual agonist and antagonist activities. This is believed to result in both a lesser amount of dopamine release from the VTA at the nAcc as well as the prevention of nicotine binding at the 42 receptors
Nicotine
Binding of nicotine at the 42 nicotinic receptor in the Ventral Tegmental Area (VTA) is believed to cause release of dopamine at the Nucleus Accumbens (nAcc)
Varenicline
Efficacy Data
Varenicline Phase 3 Studies: Efficacy Measurements: CO-Confirmed 4-Wk Continuous Abstinence Rates Wks 9-12
Point Prevalence Outcome
Varenicline: Most Common Adverse EventsFrom 12-Week Fixed-Dose, Placebo-Controlled Studies
Varenicline – Prescribing Information
Start varenicline one week before the quit date for maximum effectiveness
Recommended treatment is 12 weeks:– Days 1-3………..1 pill (0.5 mg) per day– Days 4-7………..1 pill (0.5 mg) twice a day (am & pm)– Day 8-end………1 pill (1 mg) twice a day (am & pm)
An additional course of 12 weeks for maintenance can be considered
Treatment
Counseling
– The Wisconsin Tobacco Quit Line at 1-800-QUIT-NOW.
– It’s free, confidential, and non-judgmental. – Callers are 4 times more likely to quit than
those who try to quit cold turkey.– Services are available in virtually any language.
Designed to help employees at the University of Wisconsin Hospital and Clinics quit.
A UWHC Employee Program
608-438-4517
UW-CTRI Outreach Specialist
Southern Region-Madison
Tricia Brein, MS
UW-CTRI
1930 Monroe St, Suite 200
Madison, WI 53711
608-265-4860
Fax: 608-265-3102
15
www.ctri.wisc.edu